4117 logo

General Biologicals Corporation Stock Price

TPEX:4117 Community·NT$252.4m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

4117 Share Price Performance

NT$4.15
-18.35 (-81.56%)
NT$4.15
-18.35 (-81.56%)
Price NT$4.15

4117 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Slight risk and slightly overvalued.

4 Risks
2 Rewards

General Biologicals Corporation Key Details

NT$215.7m

Revenue

NT$156.1m

Cost of Revenue

NT$59.6m

Gross Profit

-NT$406.2m

Other Expenses

NT$465.8m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
7.66
27.63%
215.93%
232.3%
View Full Analysis

About 4117

Founded
1984
Employees
n/a
CEO
Frank Lin
WebsiteView website
www.gbc.com.tw

General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening services for hepatitis and HIV; and biomaterial, such as antibody biomaterials and human plasma. Additionally, it offers a range of oral care products under the oh care brand. Further, the company serves its diagnostic solutions through clinics and laboratories. General Biologicals Corporation was founded in 1984 and is headquartered in Hsinchu City, Taiwan.

Recent 4117 News & Updates

Recent updates

No updates